pyrroles has been researched along with Hyperlipemia in 358 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.28) | 18.7374 |
| 1990's | 29 (8.10) | 18.2507 |
| 2000's | 229 (63.97) | 29.6817 |
| 2010's | 95 (26.54) | 24.3611 |
| 2020's | 4 (1.12) | 2.80 |
| Authors | Studies |
|---|---|
| Ng, A | 1 |
| Cruz-López, P; González, JG; Parmar, D; Rodriguez-Gutierrez, R; Shaikh, F | 1 |
| Bhatt, J; Dunbar, RL; Parmar, DV; Parmar, K; Rastogi, A; Thacker, HP | 1 |
| Gopalan, RK; Jalaja, R; Leela, SG; Mohan, S; Nair, MS; Somappa, SB | 1 |
| Chikazawa, M; Hioki, Y; Hirade, N; Hirose, S; Itakura, M; Kikuchi, R; Matsushita, T; Miyashita, H; Nagata, K; Shibata, T; Uchida, K; Yoshitake, J; Zhang, M | 1 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Das, DK; Das, N; Dey, S; Kesh, SB; Khan, A; Manna, K; Sikder, K | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| Cziraky, M; Jacobson, TA; Kuznik, A; Wertz, DA | 1 |
| Berg, RL; Davis, RL; Denny, JC; Feng, Q; Iwuchukwu, OF; Jiang, L; Jiang, M; Krauss, RM; McCarty, CA; Nickerson, DA; Peissig, PL; Roden, DM; Rotter, JI; Waitara, MS; Wei, WQ; Wilke, RA; Xu, H | 1 |
| Bloigu, R; Morin-Papunen, L; Piltonen, T; Puukka, K; Puurunen, J; Ruokonen, A; Savolainen, MJ; Tapanainen, JS | 1 |
| Akturk, E; Altas, Y; Atas, H; Balta, S; Can, C; Demirkol, S; Erdem, K; Korkmaz, H; Kurtoglu, E; Sincer, I; Yilmaz, M | 1 |
| Al-Mansoub, MA; Asmawi, MZ; Murugaiyah, V | 1 |
| Belagali, Y; Bhagwath, V; Maskeri, R; Ramya, K; Shoeb, A; Ullal, SD | 1 |
| Ma, X; Wang, F; Wang, M; Wang, Y; Zhao, C; Zhao, M | 1 |
| Chen, Y; Huang, A; Ku, H; Li, LC; Li, Q; Moorhead, JF; Powis, SH; Ruan, XZ; Varghese, Z; Wheeler, DC; Zhao, L | 1 |
| Awoniyi, O; Gosmanov, AR | 1 |
| An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y | 1 |
| Cunnane, G; Durcan, L; Gleeson, N; McKiernan, S | 1 |
| Ballantyne, CM; Blom, DJ; Bolognese, M; Burgess, L; Ceska, R; Hala, T; Kim, JB; Koren, MJ; Lillestol, MJ; Monsalvo, ML; Roth, E; Scott, R; Stein, EA; Toth, PD; Tsirtsonis, K; Wasserman, SM | 1 |
| Guo, YL; Li, JJ; Li, S; Li, XL; Xu, RX | 1 |
| Cen, C; Ding, X; Huang, C; Wang, C; Zhan, H | 1 |
| Doad, GJ; Kabange, W | 1 |
| Abdelbaset, M; Agha, AM; Mahmoud, SS; Negm, SA; Safar, MM | 1 |
| Chen, Y; Chen, Z; Gu, M; Lin, Y; Luo, N; Wang, J; Wang, X | 1 |
| Choudhary, PR; Sharma, MS | 1 |
| Guan, XH; Guo, WS; He, YB; Pan, AQ; Wang, JX; Xie, Y; Zhang, J; Zhang, SX | 1 |
| Hunter, ML; Mahvan, TD; Mlodinow, SG; Onysko, MK; Vandiver, JW | 1 |
| Bento, CF; Fernandes, R; Matafome, P; Pereira, P; Seiça, RM; Sena, CM | 1 |
| Baldazzi, V; Carini, M; Lapini, A; Mazzanti, R; Tassi, R | 1 |
| Baldane, S; Ipekçi, SH; Kebapçılar, L; Sözen, M | 1 |
| Adams, SP; Tsang, M; Wright, JM | 2 |
| Song, J; Sun, YZ | 1 |
| Haysom, L; Samaras, K; Stapylton, C; Wines, J | 1 |
| Hanlin, S; Kexuan, T; Ming, Y; Yuliang, W; Zejian, W | 1 |
| Ahmed, MH; Elmadhoun, WM; Hassan, AT; Husain, NE | 1 |
| Komai, E; Takemoto, M; Yokote, K | 1 |
| Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kwok, K; Riese, R; Soma, K; Wicker, P; Zuckerman, A | 1 |
| Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K | 1 |
| Adánez, G; Ayala, I; Castells, MT; García Pérez, B; Martín Castillo, A; Montes, A; Sánchez-Polo, MT | 1 |
| Albalat-Galera, R; Berzosa-Sanchez, M; Ferrer-García, JC; Herrera-Ballester, A; Sanchez-Ballester, E | 1 |
| Lindsley, CW | 1 |
| Kékes, E | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Moedas, AR; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Ai, M; Jones, PH; Matthan, NR; Otokozawa, S; Resteghini, NA; Schaefer, EJ; Stein, EA; van Himbergen, TM | 1 |
| Collier, D; Cruickshank, JK; Hughes, AD; Lacy, PS; Stanton, A; Thom, S; Thurston, H; Williams, B | 1 |
| Ai, M; Asztalos, BF; Jones, PH; Otokozawa, S; Schaefer, EJ; Stein, EA; Tanaka, A; Van Himbergen, T | 1 |
| Chen, TY; Kuo, YL; Lin, WC; Tan, TY | 1 |
| Koren, MJ; Kuznik, A; Mullins, CD; Rattinger, GB | 1 |
| Chen, IJ; Hsieh, SL; Kwan, AL; Lin, HL; Shen, KP; Wu, BN | 1 |
| Ghante, MH; Ghule, BV; Saoji, AN; Yeole, PG | 1 |
| Ageev, FT; Kulev, BD | 1 |
| Chen, YX; Fu, Y; Kong, MY; Nie, RQ; Wang, JF; Wang, XQ; Yao, YJ | 1 |
| Ak, K; Arsan, S; Eksioglu-Demiralp, E; Iqbal, O; Isbir, S; Tetik, S; Yardimci, T | 1 |
| Devine, A; Hamilton, PK; Hughes, SM; Johnston, D; Leahey, W; Lyons, KS; McVeigh, GE; Plumb, RD | 1 |
| Nikitina, NM; Rebrov, AP | 1 |
| Bonkovsky, HL; Russo, MW; Scobey, M | 1 |
| Goetghebeur, M; Jönsson, B; Lindgren, P; Merikle, E; Wagner, M | 1 |
| Adánez, G; Ayala, I; Castells, MT; Martín-Castillo, A; Pérez, BG; Polo, MT | 1 |
| Li, L; Meng, X; Qie, L; Wang, Y; Zhong, M | 1 |
| Bangit, JR; Batsell, RR; John, S; Molinella, R; Reddy, KJ; Singh, M; Varghese, S; Zaheer, MS | 1 |
| Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J | 1 |
| Celermajer, DS; Harmer, JA; Kainer, G; Mackie, FE; Rosenberg, AR | 1 |
| Näntö-Salonen, K; Niinikoski, H; Simell, O; Tanner, LM | 1 |
| Ben-Yehuda, O; Bird, S; Constance, C; Hanson, ME; Jones-Burton, C; Lee, R; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Chen, C; Huang, QY; Liu, L; Shu, J; Wasti, B; Xu, DY; Zhao, SP | 1 |
| Burke, JP; Rublee, DA | 1 |
| Cherkanova, MS; Korolenko, EC; Korolenko, TA | 1 |
| Aykaç, Y; Fentoğlu, O; Gürgan, CA; Kale, B; Kirzioğlu, FY; Oz, SG; Sönmez, Y; Sözen, T; Tonguç, MO | 1 |
| Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR | 1 |
| Foody, JM; Liu, LZ; Mendys, PM; Simpson, RJ | 1 |
| Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C | 1 |
| Joo, IW; Oh, HJ; Ryu, JH | 1 |
| Buxton, M; Dahlöf, B; Eriksson, J; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Boaz, M; Gilad, R; Lampl, Y; Lorberboym, M; Sadeh, M; Tikozky, A; Vysberg, I | 1 |
| Hu, XJ; Jia, M; Li, YP; Zhang, LR | 1 |
| Ando, D; Hirawa, N; Umemura, S; Yasuda, G | 1 |
| Strandberg, TE | 1 |
| Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C | 1 |
| Ay, ZY; Fentoğlu, Ö; Hiçyılmaz, H; Kırzıoğlu, FY; Köroğlu, BK; Orhan, H; Özdem, M; Öztürk Tonguç, M; Sert, T; Sütçü, R; Tamer, MN | 1 |
| Benjannet, S; Couture, P; Davis, HR; Hoos, L; Lamarche, B; Lemelin, V; Seidah, NG; Tremblay, AJ | 1 |
| Hu, XJ; Wei, KK; Zhang, LR; Zhang, Y | 1 |
| Rosenson, RS | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Ai, M; Asztalos, BF; Himbergen, TV; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E; Thongtang, N | 1 |
| Ji, G; Jiang, Z; Leng, L; Liu, P; Zhao, X | 1 |
| Choi, D; Chung, N; Jang, Y; Kang, SM; Lee, SH; Park, S | 1 |
| Akhtar, S; Al-Sagair, OA; Arif, JM; Salman Khan, M | 1 |
| Puszczewicz, M; Ruchala, M; Sosnowski, P; Sowinski, J; Szczepanek, E | 1 |
| John, H; Kitas, GD; Toms, TE | 1 |
| Eren, MA; Koksal, M; Sabuncu, T; Turan, MN | 1 |
| Cherkanova, MS; Johnston, TP; Kaledin, VI; Korolenko, TA; Loginova, VM; Tuzikov, FV; Tuzikova, NA | 1 |
| An, LM; Chang, WT; Chen, IJ; Lin, HL; Shen, KP; Wu, BN | 1 |
| Blanco-Colio, LM; de Teresa, E; Després, JP; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gupta, M; Langer, A; Leiter, LA; Martineau, P; Tran, T | 1 |
| Li, JJ | 1 |
| Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S | 1 |
| Inamdar, MN; Kumar, VR; Viswanatha, GL | 1 |
| Takagi, H; Umemoto, T | 1 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Iyer, D; Patil, UK; Sharma, BK | 1 |
| Fentoğlu, O; Kirzioğlu, FY; Koçak, H; Ozdem, M; Sert, T; Sütçü, R | 1 |
| Bellanger, N; Chapman, MJ; Duchene, E; El Khoury, P; Fournier, N; Guerin, M; Julia, Z; Le Goff, W; Villard, EF | 1 |
| Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L | 1 |
| Cherkanova, MS; Filjushina, EE; Johnston, TP; Kaledin, VI; Korolenko, TA; Loginova, VM; Tuzikov, FV; Tuzikova, NA | 1 |
| Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M | 1 |
| Vareka, T; Vecka, M; Vítková, D; Zák, A; Zeman, M | 1 |
| Ai, J; Ban, X; Niu, H; Sun, L; Wang, N; Xu, Y; Yang, B; Yu, Y; Zhang, R; Zhao, R | 1 |
| Narula, SC; Sangwan, A; Sharma, RK; Singh, H; Tewari, S | 1 |
| Elisaf, MS; Kostapanos, MS; Mikhailidis, DP | 1 |
| Covelli, D; Crisanti, F; De Vuono, S; Lupattelli, G; Mannarino, E; Pirro, M; Roscini, AR; Siepi, D | 1 |
| Lazareva, NV; Oshchepkova, EV | 1 |
| Farah, R; Jubran, F; Khamisy-Farah, R | 1 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Asztalos, BF; Diffenderfer, MR; Dolnikowski, GG; Lamon-Fava, S; Ooi, EM; Schaefer, EJ; Thongtang, N | 1 |
| Fu, Q; Gao, Y; Jia, M; Li, YP; Lu, PQ; Yang, SH; Zhang, LR | 1 |
| Fedacko, J; Janicko, M; Jarcuska, P; Jedlickova, L; Kmec, J; Lopuchovsky, T; Merkovska, L; Pella, D; Sabol, F; Sajty, M | 1 |
| Adamova, IY; Afanasieva, OI; Akchurin, RS; Atanesyan, RV; Ezhov, MV; Il'ina, LN; Konovalov, GA; Pokrovsky, SN; Safarova, MS | 1 |
| Velussi, M | 1 |
| Açil, T; Aksöyek, S; Atalar, E; Haznedaroglu, I; Kes, S; Ovünç, K; Ozer, N; Ozmen, F | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Redgrave, TG; Watts, GF | 2 |
| de Beer, F; Havekes, LM; Kastelein, JJ; Lansberg, PJ; Prins, MH; Smelt, AH; Trip, MD; van Dam, M; Zwart, M | 1 |
| Supanich, B | 1 |
| Asakura, H; Ishino, C; Kanno, M; Matsuda, T; Minami, S; Morishita, E; Nakao, S; Uotani, C | 1 |
| Lisker-Melman, M; Shiels, P; Sreenarasimhaiah, J | 1 |
| Dixon, JL; Shen, S; Sturek, M; Sun, GY; Vuchetich, JP; Wysocka, E | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ; Vernalis, MN | 1 |
| SoRelle, R | 1 |
| Nordøy, A | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC | 1 |
| Ceska, R; Fialova, L; Malbohan, I; Stulc, T; Zima, T | 1 |
| Amâncio, RF; Chapman, MJ; Maranhão, RC; Ramires, JA; Santos, RD; Sposito, AC | 1 |
| Baykan, M; Calapoğlu, M; Erdöl, C; Orem, A; Orem, C; Uydu, HA | 1 |
| Berk-Planken, II; Bootsma, AH; Hoogerbrugge, N; Jansen, H; Stolk, RP | 1 |
| Backes, JM; Moriarty, PM | 1 |
| Silverstein, DM | 1 |
| Aitken, M; Argent, E; Kainer, G; Mackie, FE; Rosenberg, AR | 1 |
| Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE | 1 |
| Clark, LT | 1 |
| Dixon, JL; Katwa, LC; Lee, DL; Reddy, HK; Sturek, M; Voelker, DJ; Wamhoff, BR | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Belowski, D; Herman, ZS; Kalina, Z; Kowalski, J; Madej, A; Okopień, B; Zieliński, M | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Julier, K; Mackness, MI; Neil, HA; Soedamah-Muthu, SS; Thomason, MJ | 1 |
| Betz, W; Devroey, D; Duquet, W; Velkeniers, B | 1 |
| Achimastos, A; Bairaktari, E; Elisaf, M; Karabina, SA; Tambaki, A; Tselepis, A; Tsimihodimos, V | 1 |
| De Maat, MP; Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; Van De Ree, MA | 1 |
| Akhmedzhanov, NM; Metel'kaya, VA; Oganov, RG; Raszzivin, VA; Vasiutina, EI | 1 |
| Marais, AD; McCrindle, BW; Ose, L | 1 |
| Beniashvili, M; Freiman, A; Gavish, D; Leibovitz, E; Shargorodsky, M; Zimlichman, R | 1 |
| Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K | 1 |
| Jick, H; Jick, SS; Yang, CC | 1 |
| Newman, CB; Palmer, G; Silbershatz, H; Szarek, M | 1 |
| Bedynek, A; Bilz, S; Demant, T; Keller, U; Schmitz, M; Wagner, S | 1 |
| Després, JP; Lemieux, I; Salomon, H | 1 |
| Bays, HE; McGovern, ME | 1 |
| Arsenault, M; Auclair, L; Bogaty, P; Boyer, L; Dagenais, GR; Jobin, J; Pépin, G; Poirier, P | 1 |
| Scheen, AJ | 2 |
| Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A | 1 |
| Fathi, R; Haluska, B; Isbel, N; Johnson, D; Marwick, TH; Short, L | 1 |
| Allen, J; Butler, M; Kubler, PA; Lynch, SV; Pillans, PI; Taylor, PJ | 1 |
| Johnson, R; Manfredi, F; Ormiston, T; Reus, VI; Wolkowitz, OM | 1 |
| Alexy, T; Czopf, J; Habon, T; Horvath, B; Juricskay, I; Kesmarky, G; Koltai, K; Marton, Z; Szapary, L; Szots, M; Toth, K | 1 |
| Andrus, MR | 1 |
| Corrales, MA; Gonzalez-Santos, P; Moliz, M; Sanchez-Chaparro, MA; Valdivielso, P; Valera, A | 1 |
| Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Milionis, HJ; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Bhansali, A; Gupta, A; Gupta, V; Thapar, S | 1 |
| Baumstark, MW; Friedrich, I; Hauck, P; Hoffmann, MM; März, W; Nickell, HH; Schmitz, H; Weltzien, P; Wieland, H; Winkler, K | 1 |
| Nash, DT | 1 |
| Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Bhatia, GS; Hughes, EA; Sosin, MD; Sutton, B | 1 |
| Gürel, CV; Güzelsoy, D; Kaya, A; Tekin, A; Tekin, G; Ulutin, T; Yiğit, Z | 1 |
| Laustsen, G; Wimett, L | 1 |
| Fan, Q; Huang, K; Li, R; Liu, X; Tu, L; Yao, H | 1 |
| Chu, CS; Lai, WT; Lee, KT; Sheu, SH; Tsai, LY; Voon, WC; Yen, HW | 1 |
| Athyros, VG; Bouloukos, VI; Daskalopoulou, SS; Kakafika, AI; Langer, A; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Athyros, VG; Bairaktari, ET; Elisaf, MS; Kakafika, AI; Milionis, HJ; Seferiadis, KI; Tsouli, SG | 1 |
| Barrios, V; Campuzano, R; Catalán, P; Megías, A; Moya, JL; Muriel, A; Recarte, MA; Ruiz, S; Tomás, JP | 1 |
| Emri, G; Harangi, M; Paragh, G; Remenyik, E; Seres, I; Szilvássy, Z; Varga, Z | 1 |
| Hunninghake, DB; Koren, MJ | 1 |
| Alcaraz Tafalla, MS; Carrillo Alcaraz, A; Illán Gómez, F; Pascual Díaz, M | 1 |
| Captain, BK; Harris, WS; Jones, PG; O'Keefe, JH | 1 |
| Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM | 1 |
| Benz, R; Suter, PM | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Abe, Y; Kushiya, F; Nakasaki, T; Nobori, T; Noda, M; Ooi, K; Sakaguchi, A; Sakurai, Y; Shiku, H; Tsukada, T; Wada, H | 1 |
| Berezovsky, A; Laszt, A; London, D; Magen, E; Mishal, J; Priluk, R; Viskoper, R; Yosefy, C | 1 |
| Satish, B; Unnikrishnan, D | 1 |
| Belowski, D; Herman, ZS; Huzarska, M; Kulach, A; Madej, A; Okopien, B; Stachura-Kulach, A; Zielinski, M | 1 |
| Baykan, M; Eminagaoglu, S; Gökçe, M; Orem, A; Orem, C; Uydu, HA; Yilmaz, R | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Downey, J; Jones, PH; Karalis, DG; McKenney, JM | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Brock, CM; Pitcock, J | 1 |
| Ishii, T; Kaneki, M; Miyauchi, A; Nagakura, C; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y | 2 |
| Farmer, JA | 2 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Haberka, M; Herman, ZS; Krysiak, R; Okopien, B | 1 |
| Cárcamo, CA; Celedón, C; Nygren, CE; Paulós, CP | 1 |
| Haskard, DO; Lunnon, MW; Mandryko, V; Naoumova, RP; Randi, AM; Wibaut-Berlaimont, V | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Badaracco, R; Brizuela, M; Cialzeta, JR; Doval, H; Farías, EF; Franciosi, V; Macin, SM; Medina, F; Perna, ER; Tajer, C | 1 |
| Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S | 1 |
| Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L | 1 |
| Akcay, A; Bilgi, M; Bozbas, H; Kanbay, M; Muderrisoglu, H; Ozdemir, FN; Ulus, T; Yildirir, A | 1 |
| Cowie, MR | 1 |
| Fujita, H; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Murata, I; Okubo, M; Sano, K; Tsuchiya, K; Yokoyama, H; Zhou, X | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Dohi, Y; Ohashi, M; Sato, K; Sugiyama, M; Takase, H; Ueda, R | 1 |
| Burton, I; Koshman, SL; Lalonde, LD; Pearson, GJ; Tymchak, WJ | 1 |
| Albertini, JP; Charniot, JC; Hantz, E; Le Moyec, L; Valensi, P | 1 |
| Athyros, VG; Didangelos, TP; Elisaf, M; Kakafika, AI; Karagiannis, A; Kleta, D; Mikhailidis, DP; Papageorgiou, AA; Peletidou, A; Tziomalos, K | 1 |
| Aso, Y; Inukai, T; Inukai, Y; Matsumoto, S; Matsutomo, R; Takebayashi, K; Wakabayashi, S | 1 |
| Ferns, GA; Ghayour-Mobarhan, M; Lamb, DJ; Livingstone, C; Taylor, A; Vaidya, N; Wang, T | 1 |
| Cohen, H; Plakogiannis, R; Taft, D | 1 |
| Briestensky, J; Jamborova, G; Jaynes, R; Kopecky, M; Nachtigal, P; Pospechova, K; Pospisilova, N; Santar, I; Semecky, V; Smahelova, A; Solichova, D; Zdansky, P | 1 |
| Arístegui, R; Artieda, M; Cenarro, A; Civeira, F; Díaz, C; Gañán, A; Gonzalvo, C; Meriño-Ibarra, E; Pocoví, M; Sol, JM | 1 |
| Koren, MJ | 1 |
| Avcu, F; Ural, AU | 1 |
| Beck, T; Burgstahler, C; Heuschmid, M; Kopp, AF; Kuettner, A; Reimann, A; Schroeder, S | 1 |
| Cairns, T; Cook, HT; Elliot, V | 1 |
| Donkin, SS; Elkin, RG; Hengstschläger-Ottnad, E; Schneider, WJ; Zhong, Y | 1 |
| Kuryata, OV; Yegorova, YV | 1 |
| Clearfield, M | 1 |
| Day, CA; Jacob, RF; Mason, RP; Walter, MF | 1 |
| Lynch, T | 1 |
| He, JC; Li, WX; Liu, YM; Liu, YY; Ma, XW; Qiao, CD; Shang, DY; Wang, JY; Yan, X; Yang, JG; Zhao, L | 1 |
| Borucki, K; Luley, C; Makarova, R; Schmidt-Lucke, C; Taneva, E; Westphal, S; Wiens, L | 1 |
| Dallinga-Thie, GM; Hattori, H; Jansen, H; Sijbrands, EJ; van Tol, A; van Vark-van der Zee, LC | 1 |
| Apperson-Hansen, C; Churchill, T; Crowe, T; Lin, S; Loyd, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wang, C; Wolski, K | 1 |
| Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S | 1 |
| Barrett, PH; Chan, DC; Nguyen, MN; Watts, GF | 1 |
| Arcas, I; Ayala, I; Castells, MT; Corral, J; García-Pérez, B; Hernández-Espinosa, D; Martín-Castillo, A; Miñano, A; Vicente, V | 1 |
| Elisaf, MS; Filippatos, TD; Ganotakis, ES; Gazi, IF; Goudevenos, J; Kostapanos, M; Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Cipriano, P; Di Marino, L; Gentile, A; Iovine, C; Lilli, S; Patti, L; Riccardi, G; Rivellese, AA | 1 |
| Hiasa, Y; Hosokawa, S; Kishi, K; Miyajima, H; Ogata, T; Ogura, R; Ohara, Y; Ohtani, R; Suzuki, N; Takahashi, T; Tomokane, T; Yuba, K | 1 |
| Abraham, J; Alla, V; Bonkovsky, HL; Chalasani, NP; Raina, D; Siddiqui, J; Wu, GY | 1 |
| Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G | 1 |
| Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Balakhonova, TV; Kukharchuk, VV; Masenko, VP; Pogorelova, OA; Susekov, AV; Tripoten', MI; Zubareva, Mi | 1 |
| Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP | 1 |
| Moulik, N; Patil, N; Rajadhyaksha, G; Save, V | 1 |
| Hosoya, T; Kawamoto, S; Kawamura, T; Miyazaki, Y | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Hammervold, T; Howe, PR; Meyer, BJ; Rustan, AC | 1 |
| Fu, LC; Gao, X; Hu, YJ | 1 |
| Clarke, PJ; Grobler, MP; Levison, DB; Liew, D; Magliano, DJ; Rogers, SL; Webb, K | 1 |
| Bechis, G; Delliaux, S; Jammes, Y; Lesavre, N; Oliver, C; Paganelli, F; Steinberg, JG | 1 |
| Ezhov, MV; Kukharchuk, VV; Naumov, VG; Samoĭlenko, EIu; Sergienko, IV; Tvorogova, MG | 1 |
| Balakhonova, TV; Kukharchuk, VV; Kulev, BD; Masenko, VP; Pogorelova, OA; Rogozova, AN; Rozhkova, TA; Susekov, AV; Tripoten', MI; Zubareva, MIu | 1 |
| Badyal, DK; Calton, R; Chatley, P; Khosla, PP | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Caspers, N; Choi, C; Dillon, L; Hanselman, JC; Harris, MS; Larsen, SD; Lin, Z; Lu, G; Pavlovsky, A; Pfefferkorn, JA; Robertson, A; Sekerke, C; Song, Y; Trivedi, BK | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Bratton, LD; Caspers, N; Chen, H; Cheng, XM; Choi, C; Dillon, L; Eberstadt, M; Erasga, N; Hanselman, JC; Harris, MS; Larsen, SD; Lee, C; Lin, Z; Lu, G; Mertz, T; Miller, SR; Olsen, K; Pavlovsky, A; Pfefferkorn, JA; Poel, TJ; Robertson, A; Sekerke, C; Song, Y; Sorenson, RJ; Sun, KL; Trivedi, BK; Unangst, PC | 1 |
| Caracchini, R; Gresele, P; Guglielmini, G; Guzzetta, M; Impagnatiello, F; Momi, S; Monopoli, A; Olivieri, R | 1 |
| Cizek, L; Horakova, D; Janout, V; Janoutova, G; Karpisek, M; Kollar, P; Kotolova, H; Lichnovska, R; Ochmanova, R; Stejskal, D; Yahia, RB | 1 |
| Arca, M; Gaspardone, A | 1 |
| Antonini, R; Antonini, TM; Arca, M; Fraioli, A; Letizia, C; Luigi, P; Maddaloni, M; Mastrantoni, M; Montali, A; Pigna, G | 1 |
| Bała, A; Broncel, M; Chojnowska-Jezierska, J; Duchnowicz, P; Koter-Michalak, M; Wojsznis, W | 1 |
| Ankola, DD; Chandraiah, G; Kumar, MN; Meena, AK; Rao, PR; Ratnam, DV | 1 |
| Adamidou, A; Giannopoulos, S; Hatzitolios, AI; Kosmidou, MS; Milionis, HJ; Parharidis, G; Raikos, N | 1 |
| Ai, M; Asztalos, BF; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E | 1 |
| Chu, CH; Chuang, MJ; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Wang, MC; Wei, MC | 1 |
| Fidani, L; Giannopoulos, S; Goulas, A; Hatzitolios, AI; Kosmidou, M; Mirtsou, V; Molyva, D | 1 |
| Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG | 1 |
| Arsova, V; Jurukovska-Nospal, M; Levchanska, J; Sidovska-Ivanovska, B | 1 |
| Başar, MM; Batislam, E; Doğru, MT; Ebinç, H; Güneri, M; Simşek, A; Yuvanç, E | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Lea, AP; McTavish, D | 1 |
| Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M | 1 |
| Alaupovic, P; Black, DM; Davignon, J; Heinonen, T; Leiter, L; Lupien, PJ; Ooi, TC; Shurzinske, L; Sniderman, AD; Sorisky, A; Tan, MH; Tremblay, G | 1 |
| Kupecz, D | 1 |
| Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S | 1 |
| Davignon, J | 1 |
| Fong, NT; Yee, HS | 1 |
| Liguori, E; Sarcinella, R | 1 |
| Strandberg, TE; Tikkanen, MJ; Vanhanen, H | 1 |
| Connelly, PW; Hegele, RA; Little, JA | 1 |
| Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Miltiadous, GA; Tsimihodimos, VK; Tzallas, CS | 1 |
| Alfon, J; Badimon, L; Pueyo Palazon, C; Royo, T | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Gänzer, H; Kirchmair, R; Patsch, JR; Sturm, W | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Martín, T; Murillas, J; Portero, JL; Ramos, A | 1 |
| Rodrigues, M; Sinzinger, H | 1 |
| Eliot, LA; Jamali, F | 1 |
| Desager, JP; Descamps, O; Heller, F; Hondekijn, JC | 1 |
| Farnier, M | 1 |
| Chapman, MJ; Farnier, M; Guerin, M; Lassel, TS; Le Goff, W | 1 |
| Cooper, A; Kratzer, S; Pershad, A | 1 |
| Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M | 1 |
| Cernigoi, AM; Merni, M; Tortul, C; Velussi, M | 1 |
| Hufnagel, G; Kossari, N; Michel, C; Mignon, F; Queffeulou, G; Vrtovsnik, F | 1 |
| Böhmig, G; Demetriou, D; Hörl, WH; Schmaldienst, S; Shabpar, A; Watschinger, B | 1 |
| Caslake, M; Packard, C; Shepherd, J | 1 |
| Spielberg, T | 1 |
| Darioli, R; Keller, U; Mordasini, R; Noseda, G; Riesen, W; Schaffhauser, B; Shokry, A | 1 |
| Black, D; Davila, M; Knapp, H; Schrott, HG; Shurzinske, L | 1 |
| Branzi, A; Carinci, V; Magelli, C; Magnani, G; Potena, L; Reggiani, LB | 1 |
| Brophy, DF; Gehr, TW; Holdford, DA; Kennedy, DT; Wallace, JF | 1 |
| DiTusa, L; Luzier, AB | 1 |
| El Menjawi, I; Fladerer, P; Krause, R; Pohanka, E; Wenisch, C | 1 |
| Aguilar-Salinas, CA; Alvarado Vega, A; Angélica Gómez-Díaz, R; Eduardo Romero-Nava, L; Gómez-Pérez, FJ; Guillén, LE; Gulías-Herrero, A; Meaney, E; Mendoza Pérez, E; Moguel, R; Novoa, G; Posadas-Romero, C; Salinas-Orozco, S; Vázquez-Chávez, C | 1 |
| Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS | 1 |
| Armitage, J; Betteridge, DJ; Colhoun, H | 1 |
| Stein, EA | 2 |
| Amore, C; Baccante, G; Cuccurullo, F; Di Castelnuovo, A; Di Febbo, C; Donati, MB; Iacoviello, L; Porreca, E | 1 |
| Frost, RJ; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Aragoncillo, P; Cachofeiro, V; Díaz, C; Hernández, G; Lahera, V; Maeso, R; Navarro-Cid, J; Ruilope, LM; Vázquez-Pérez, S | 1 |
| Campeau, L | 1 |
| Burkhardt, K; Hauser, IA; Koch, C; Mayer-Kadner, I; Renders, L; Schärffe, S; Schmieder, RE; Veelken, R | 1 |
| Bairaktari, E; Elisaf, MS; Kiortisis, DN; Millionis, H | 1 |
| Goldner, D; Insull, W; Kafonek, S; Zieve, F | 1 |
| Arai, Y; Funatsu, T; Kakuta, H; Miyata, K; Suzuki, K; Tanaka, H | 1 |
| Aragoncillo, P; Cachofeiro, V; Diaz, C; Hernández, G; Lahera, V; Maeso, R; Navarro-Cid, J; Ruilope, LM | 1 |
| Arístegui, R; Canudas, J; Cenarro, A; Civeira, F; Díaz, C; Garcí-Otín, AL; Hernández, G; Masramon, X; Pocoví, M; Sol, JM | 1 |
| Aoki, T; Kitahara, M; Saito, Y; Sato, F; Suzuki, H; Tamaki, T; Yamazaki, H | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D | 1 |
| Mertens, A; Muls, E; Vansant, G | 1 |
| Black, DM; McCormick, LS; McKenney, JM; Schaefer, EJ; Watkins, ML | 1 |
| Schwartz, JB | 1 |
| Ceska, R; Haas, T; Hradec, J; Malik, J; Melenovsky, V; Simek, J; Wichterle, D | 1 |
| Bazalo, GR | 1 |
| Dixon, JL; Hill, BJ; Sturek, M | 1 |
| Goa, KL; Malhotra, HS | 1 |
| Kobayashi, J; Maruyama, T; Masuda, M; Shinomiya, M | 1 |
| Hiyoshi, H; Ikuta, H; Ito, M; Kurusu, N; Okada, T; Saeki, T; Shinmyo, D; Tanaka, H; Tanaka, K; Yanagimachi, M; Yoshida, I | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Jialal, I; Stein, DT | 1 |
| Bairaktari, E; Chapman, MJ; Elisaf, M; Goudevenos, JA; Karabina, SA; Tambaki, AP; Tselepis, AD; Tsimihodimos, V | 1 |
| Cooke, JP; Glassford, AJ; Heeschen, C; Weis, M | 1 |
| Adeli, K; Cheung, RC; Parris, W; Pontrelli, L | 1 |
| Karalis, DG; Ross, AM; Scott, R; Vacari, RM; Zarren, H | 1 |
| Celik, S; Erdöl, C; Kural, BV; Orem, A; Orem, C; Uydu, HA | 1 |
| Chong, CC; Harris, KP; Wheeler, DC | 1 |
| Barrett, PH; Chan, DC; James, AP; Mamo, JC; Martins, IJ; Mori, TA; Redgrave, TG; Watts, GF | 1 |
| Iliff, RD | 1 |
| Baker, D; Hamilton, G; Jagroop, IA; Mikhailidis, DP; Myint, F; Seifalian, AM; Youssef, F | 1 |
| de Koning, EJ; Gaillard, CA; Honing, ML; Rabelink, TJ; Stroes, ES; van Etten, RW | 1 |
| Delaval, D; Després, JP; Lemieux, I; Salomon, H | 1 |
| Acevedo, M; Francis, G; Lauer, MS; Sprecher, DL | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Banga, JD; Bots, ML; Huisman, MV; Stolk, RP; van de Ree, MA; van Venrooij, FV | 1 |
| Berk-Planken, I; de Konig, I; Hoogerbrugge, N; Jansen, H; Stolk, R | 1 |
| Simila, S | 1 |
32 review(s) available for pyrroles and Hyperlipemia
| Article | Year |
|---|---|
Liptruzet: a combination of ezetimibe and atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Combinations; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Lipid-lowering efficacy of atorvastatin.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Controlled Before-After Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Pyrroles; Randomized Controlled Trials as Topic; Sex Factors; Triglycerides | 2015 |
Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Approval; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Insulin Resistance; Pyrroles | 2015 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Drug-induced liver injury associated with statins.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Autoimmunity; Biomarkers; Biopsy; Chemical and Drug Induced Liver Injury; Chronic Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Liver; Liver Diseases; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Assessment; Treatment Outcome; Young Adult | 2009 |
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
Rheumatoid arthritis: is it a coronary heart disease equivalent?
Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Risk Factors | 2011 |
Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Heart Diseases; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Lipid lowering efficacy of atorvastatin.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2012 |
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB.
Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Tissue Distribution | 2003 |
Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.
Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles | 2003 |
Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Atorvastatin; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; International Normalized Ratio; Male; Patient Compliance; Pyrroles; Simvastatin; Venous Thrombosis; Warfarin | 2004 |
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric Acid; Combined Modality Therapy; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Niacin; Pyrroles; Risk Factors; Smoking Cessation; Triglycerides; Weight Loss; World Health Organization | 2004 |
A closer look at Caduet. The new generation of combination treatment.
Topics: Amlodipine; Drug Combinations; Drug Costs; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Pyrroles; United States | 2005 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles; Risk Factors; Treatment Outcome | 2005 |
A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2007 |
Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
Topics: Angioplasty, Balloon; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Myocardial Ischemia; Pyrroles | 2007 |
Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles | 1997 |
Advances in drug treatment of dyslipidemia: focus on atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Triglycerides | 1998 |
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Treatment Outcome | 1998 |
[Statins in diabetic hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles; Risk Factors; Triglycerides | 1999 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
The role of small, dense low density lipoprotein (LDL): a new look.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pyrroles | 2000 |
Lipid lowering and coronary bypass graft surgery.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Postoperative Period; Pyrroles; Randomized Controlled Trials as Topic | 2000 |
[Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, VLDL; Liver; Pyrroles; Receptors, LDL; Triglycerides | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
Lipid-lowering medications: what the new guidelines and data mean to women.
Topics: Age Factors; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Practice Guidelines as Topic; Pyrroles; Triglycerides | 2001 |
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
153 trial(s) available for pyrroles and Hyperlipemia
| Article | Year |
|---|---|
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
Topics: Adult; Double-Blind Method; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Phenylpropionates; Pyrroles; Triglycerides | 2022 |
Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Phenylpropionates; Placebos; Postprandial Period; PPAR alpha; PPAR gamma; Pyrroles; Triglycerides | 2020 |
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Insulin-Secreting Cells; Middle Aged; Overweight; Polycystic Ovary Syndrome; Pyrroles | 2013 |
Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.
Topics: Arginine; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Stenosis; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome; Turkey | 2014 |
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Azetidines; Cholesterol, LDL; Combined Modality Therapy; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Least-Squares Analysis; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2014 |
Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2014 |
[Treatment of combined hyperlipidemia patients by jiangzhi tongluo soft capsule combined atorvastatin calcium tablet: a clinical study].
Topics: Adult; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2014 |
[Clinical trials for treatment of primary hyperlipidemia by using acupuncture in combination with Lipitor].
Topics: Acupuncture Therapy; Adult; Aged; Atorvastatin; Cholesterol, LDL; Combined Modality Therapy; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2015 |
Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Feasibility Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2008 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.
Topics: Absorption; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol; Diabetes Complications; Female; Fluorobenzenes; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Phytosterols; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sterols; Sulfonamides | 2009 |
Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
Topics: Aorta; Atorvastatin; Blood Pressure; Brachial Artery; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Placebos; Pulsatile Flow; Pyrroles; Radial Artery; Treatment Outcome | 2009 |
[Effect of various approaches to therapy with statins in high risk patients from the point of view of vascular endothelium].
Topics: Aged; Atorvastatin; Brachial Artery; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Vasodilation | 2009 |
Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
Topics: Adenosine Diphosphate; Aged; Aspirin; Atorvastatin; Clopidogrel; Comorbidity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Prospective Studies; Pyrroles; Ticlopidine | 2010 |
Statins have beneficial effects on platelet free radical activity and intracellular distribution of GTPases in hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Blood Platelets; Double-Blind Method; Free Radicals; GTP Phosphohydrolases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Nitric Oxide; Pyrroles; rac GTP-Binding Proteins; rho GTP-Binding Proteins; Superoxides | 2010 |
[The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia].
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome; Vascular Resistance | 2009 |
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Markov Chains; Middle Aged; Myocardial Infarction; Probability; Pyrroles; Risk Assessment; Simvastatin; Survival Rate; Treatment Outcome | 2009 |
Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity.
Topics: Aged; Anticholesteremic Agents; Arteries; Atorvastatin; Compliance; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles | 2009 |
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin | 2008 |
HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
Topics: Adolescent; Atorvastatin; Blood Pressure; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2010 |
Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine.
Topics: Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Hyperlipidemias; Intercellular Adhesion Molecule-1; Male; Matrix Metalloproteinase 9; Medicine, Chinese Traditional; Middle Aged; P-Selectin; Pyrroles; Triglycerides | 2010 |
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Topics: Adult; Atorvastatin; Biotransformation; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Female; Fenofibrate; Gemfibrozil; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lactones; Male; Middle Aged; Pyrroles | 2011 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Disease; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Young Adult | 2010 |
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Markov Chains; Medication Adherence; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Risk Factors | 2010 |
CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Topics: Alleles; Asian People; Atorvastatin; China; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Pyrroles; Sex Factors; Simvastatin | 2011 |
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Probucol; Prospective Studies; Pyrroles; Young Adult | 2010 |
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men.
Topics: Adult; Atorvastatin; Cholesterol; Drug Administration Schedule; Duodenum; Gene Expression Regulation; Heptanoic Acids; Humans; Hyperlipidemias; Intestinal Mucosa; Intestines; Male; Membrane Proteins; Membrane Transport Proteins; Pyrroles; RNA, Messenger | 2011 |
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Topics: Acetates; Acute Coronary Syndrome; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles | 2011 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
Topics: Adiponectin; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus; Female; Fluorobenzenes; Glucose; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sulfonamides; Triglycerides | 2011 |
Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.
Topics: Adult; Aged; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Fasting; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides; Young Adult | 2012 |
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients.
Topics: Adolescent; Adult; Aged; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oxidative Stress; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2011 |
Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACT
Topics: Aged; Asian People; Atherosclerosis; Atorvastatin; Body Mass Index; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Male; Middle Aged; Pyrroles; Risk; White People | 2012 |
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome | 2013 |
Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Lipids; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols | 2012 |
Effects of atorvastatin on human C-reactive protein metabolism.
Topics: Atorvastatin; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kinetics; Male; Middle Aged; Pyrroles | 2013 |
Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Slovakia; Treatment Outcome | 2013 |
Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Component Removal; Chi-Square Distribution; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Drug Resistance; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Russia; Time Factors; Treatment Outcome; Vascular Patency | 2013 |
Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Topics: Adult; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cholesterol; Coronary Artery Disease; Fatty Acids; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; L-Selectin; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Topics: Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Fasting; Fatty Acids, Nonesterified; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Obesity; Placebos; Pyrroles | 2002 |
Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia.
Topics: Aged; Anticholesteremic Agents; Antigens; Atorvastatin; Blood Glucose; Factor VII; Female; Fibrinogen; Hemostasis; Heptanoic Acids; Humans; Hyperlipidemias; Isoantigens; Male; Middle Aged; Pyrroles; Risk Factors; Thrombosis; Triglycerides | 2002 |
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Topics: Adult; Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2002 |
Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins.
Topics: Adult; Aged; Analysis of Variance; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Chylomicrons; Dose-Response Relationship, Drug; Drug Administration Schedule; Fat Emulsions, Intravenous; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Particle Size; Probability; Pyrroles; Triglycerides | 2003 |
Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant.
Topics: Aged; Alleles; Atorvastatin; Black People; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Genetic Variation; Heptanoic Acids; Heterozygote; Humans; Hyperlipidemias; Lipase; Liver; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Sex Characteristics; White People | 2003 |
Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Transplantation; Prospective Studies; Pyrroles; Risk Factors | 2003 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors | 2003 |
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Simvastatin | 2003 |
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Myocardial Ischemia; Patient Compliance; Probability; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome | 2003 |
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Factor VIIIa; Female; Fibrinogen; Hemostatics; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pyrroles; Risk Factors; Time Factors; Tissue Plasminogen Activator; von Willebrand Factor | 2003 |
Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Apolipoproteins B; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrroles; Severity of Illness Index; Triglycerides | 2003 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2003 |
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Kinetics; Leucine; Lipids; Male; Middle Aged; Pyrroles | 2004 |
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins C; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2003 |
Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris.
Topics: Aged; Angina, Unstable; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Pyrroles | 2003 |
The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Brachial Artery; Carotid Artery, Common; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tunica Intima; Tunica Media; Ultrasonography | 2004 |
Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
Topics: Adult; Aged; Area Under Curve; Atorvastatin; Cholesterol; Cyclosporine; Drug Interactions; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrroles; Treatment Outcome | 2004 |
Hormonal changes with cholesterol reduction: a double-blind pilot study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Pyrroles | 2004 |
Atorvastatin in dyslipidaemia of the nephrotic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Nephrotic Syndrome; Prospective Studies; Pyrroles | 2003 |
Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema.
Topics: Administration, Oral; Atorvastatin; Chemotherapy, Adjuvant; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Exudates and Transudates; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Laser Coagulation; Lipoproteins, LDL; Macular Edema; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides; Visual Acuity | 2004 |
Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Topics: Adult; Aged; Atorvastatin; Drug Therapy, Combination; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Liver Function Tests; Male; Middle Aged; Pyrroles; Time Factors | 2004 |
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, HDL; Coronary Disease; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles | 2004 |
Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Practice Guidelines as Topic; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2004 |
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Topics: Atorvastatin; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2004 |
Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage.
Topics: Adult; Aged; Aryldialkylphosphatase; Atorvastatin; Cholesterol; Comet Assay; DNA Damage; Female; Heptanoic Acids; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Neutrophils; Oxidative Stress; Pyrroles; Thiobarbituric Acid Reactive Substances | 2004 |
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Topics: Adult; Aged; Ambulatory Care Facilities; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Disease Management; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Managed Care Programs; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides; United States | 2004 |
Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2004 |
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis.
Topics: Adult; Aged; Anion Exchange Resins; Atorvastatin; Electrophoresis, Agar Gel; Epichlorohydrin; Female; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Resins, Synthetic | 2005 |
Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Ascorbic Acid; Atorvastatin; Blood Pressure; Brachial Artery; Cross-Sectional Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles | 2004 |
Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2005 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Male; Middle Aged; Pyrroles | 2005 |
Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Chemokine CCL2; Double-Blind Method; Drug Administration Schedule; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Statistics, Nonparametric | 2005 |
Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia.
Topics: Aged; Atorvastatin; Chile; Community Pharmacy Services; Drug-Related Side Effects and Adverse Reactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Pyrroles; Quality of Life | 2005 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke | 2005 |
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Acute-Phase Proteins; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Female; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Secondary Prevention; Syndrome | 2005 |
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides | 2005 |
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
Topics: Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Outpatients; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound.
Topics: Aged; Atorvastatin; Coronary Stenosis; Drug Administration Schedule; Echocardiography, Three-Dimensional; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Reproducibility of Results; Ultrasonography, Interventional | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.
Topics: Aged; Atorvastatin; Cholesterol; Cluster Analysis; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Nuclear Magnetic Resonance, Biomolecular; Principal Component Analysis; Pyrroles; Reproducibility of Results; Simvastatin | 2005 |
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Obesity; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Risk Reduction Behavior | 2005 |
The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles | 2005 |
Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia.
Topics: Atorvastatin; Cholesterol; Chronotherapy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2005 |
Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Topics: Adult; Aged; Atorvastatin; Bezafibrate; Cytosine; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipids; Lipoproteins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrroles; Reference Values; Thymine | 2005 |
Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal.
Topics: Adult; Aged; Atorvastatin; Brachial Artery; Double-Blind Method; Drug Administration Schedule; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors; Vasodilation; Withholding Treatment | 2006 |
Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Safety; Triglycerides | 2006 |
Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.
Topics: Aged; Apolipoprotein A-V; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins E; Atorvastatin; Diabetes Complications; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genetic Variation; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Placebos; Pyrroles; Triglycerides | 2006 |
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Topics: Adaptation, Physiological; Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Prospective Studies; Pyrroles; Risk Factors; Single-Blind Method; Triglycerides; Ultrasonography, Interventional; Vasculitis | 2006 |
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
Topics: Abdominal Fat; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Omega-3; Fish Oils; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Lipoproteins, HDL; Male; Middle Aged; Obesity; Placebos; Pyrroles; Treatment Outcome | 2006 |
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study).
Topics: Atorvastatin; Blood Proteins; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2006 |
Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction.
Topics: Acetylcholine; Analysis of Variance; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Vessels; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Pyrroles; Regression Analysis; Time Factors | 2006 |
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment.
Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles | 2007 |
Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
Topics: Adiponectin; Aged; Atorvastatin; Bezafibrate; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2007 |
[Randomized FARVATER Study. Part 1. Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Male; Mass Screening; Middle Aged; Pyrroles | 2006 |
[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Female; Headache; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Niacin; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Effect of atorvastatin on type 2 diabetic dyslipidemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Superoxide Dismutase; Time Factors; Treatment Outcome; Triglycerides | 2006 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
Topics: Animals; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fish Oils; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipid Metabolism; Lipids; Lipoproteins, IDL; Lipoproteins, VLDL; Male; Middle Aged; Pyridines; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2007 |
Statins alter oxidant-antioxidant status and lower exercise-induced oxidative stress.
Topics: Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Exercise; Female; Heptanoic Acids; Humans; Hyperlipidemias; Isometric Contraction; Longitudinal Studies; Male; Middle Aged; Muscle Fibers, Skeletal; Oxidative Stress; Oxygen Consumption; Pyrroles; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances | 2007 |
[Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Inflammation; Lipids; Male; Myocardial Ischemia; Postprandial Period; Pyrroles; Treatment Outcome | 2007 |
[Randomized FARVATER study. Part 2. Effect of atorvastatin on endothelial function, distensibility and stiffness of vascular wall].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles | 2007 |
Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2007 |
Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Endothelin-1; Endothelium, Vascular; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2007 |
Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pyrroles; Simvastatin; Sodium-Potassium-Exchanging ATPase; Triglycerides | 2007 |
Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biological Transport; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Erythrocytes; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Linear Models; Lithium; Male; Middle Aged; Pyrroles; Sodium; Triglycerides | 2008 |
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
Topics: Aged; Atorvastatin; Cell Count; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Leptin; Male; Middle Aged; Pyrroles | 2008 |
Effects of statin treatment on serum sex steroids levels and autonomic and erectile function.
Topics: Adult; Atorvastatin; Autonomic Nervous System; Follow-Up Studies; Gonadal Steroid Hormones; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Libido; Lipids; Male; Middle Aged; Penile Erection; Pyrroles | 2008 |
Atorvastatin--a new lipid-lowering drug.
Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Ketoconazole; Pyrroles | 1997 |
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides | 1997 |
Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Diet; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Safety | 1997 |
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Male; Middle Aged; Niacin; Pyrroles; Treatment Outcome; Triglycerides; United States | 1998 |
Effect of statins on C-reactive protein in patients with coronary artery disease.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1999 |
[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indoles; Pyrroles | 1999 |
[AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 1999 |
Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 1999 |
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides | 2000 |
Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 1999 |
Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Peritoneal Dialysis; Prospective Studies; Pyrroles; Triglycerides; Uremia | 2000 |
Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cyclosporine; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Liver Function Tests; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles | 2000 |
High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Regression Analysis; Simvastatin; Triglycerides | 2000 |
Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diet; Factor VII; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles | 2000 |
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric | 2001 |
Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cyclosporine; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyridines; Pyrroles; Safety | 2001 |
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Drug Combinations; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2000 |
Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Bezafibrate; DNA; Double-Blind Method; Exons; Female; Genotype; Heptanoic Acids; Hexosaminidases; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Polymorphism, Genetic; Pyrroles | 2001 |
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
Topics: Adult; Apolipoprotein E3; Apolipoproteins E; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Double-Blind Method; Energy Intake; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Obesity; Polymerase Chain Reaction; Postprandial Period; Pyrroles; Triglycerides | 2001 |
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pyrroles | 2001 |
The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Placebos; Pyrroles; Time Factors; Triglycerides | 2001 |
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Topics: Adult; Arm; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Image Processing, Computer-Assisted; Male; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Regional Blood Flow; Regression Analysis; Triglycerides; Ultrasonography, Doppler, Duplex | 2001 |
Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects.
Topics: Aged; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Blood Glucose; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2001 |
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Esterases; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins, LDL; Macrophages; Phospholipases A; Pyrroles | 2002 |
Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Topics: Apolipoproteins B; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Peptide Fragments; Pyrroles | 2002 |
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Patient Compliance; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Placebos; Pyrroles; Treatment Outcome | 2002 |
Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test.
Topics: Anticholesteremic Agents; Atorvastatin; Body Mass Index; Breath Tests; Carbon Dioxide; Carbon Isotopes; Cholesterol; Chylomicron Remnants; Chylomicrons; Double-Blind Method; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Obesity; Placebos; Pyrroles; Time Factors; Triglycerides; Viscera | 2002 |
Weekly versus daily dosing of atorvastatin.
Topics: Adult; Aged; Analysis of Variance; Atorvastatin; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pilot Projects; Pyrroles; United States | 2002 |
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.
Topics: Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2002 |
Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.
Topics: Atorvastatin; Diet; Double-Blind Method; Drug Synergism; Exercise; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Obesity; Placebos; Pyrroles; Risk Factors | 2002 |
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides | 2002 |
Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged; Placebos; Pyrroles; Smoking; Vasodilation | 2002 |
Atorvastatin, diabetic dyslipidemia, and cognitive functioning.
Topics: Aged; Atorvastatin; Cholesterol; Cognition; Diabetes Complications; Diabetes Mellitus; Fasting; Heptanoic Acids; Humans; Hyperlipidemias; Middle Aged; Pyrroles; Time Factors; Triglycerides | 2002 |
174 other study(ies) available for pyrroles and Hyperlipemia
| Article | Year |
|---|---|
Mind the lipids: hyperlipidaemia resultant from JAK inhibitor use in inflammatory bowel disease.
Topics: Humans; Hyperlipidemias; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Lipids; Pyrroles | 2021 |
Anti-hyperlipidemic potential of natural product based labdane-pyrroles via inhibition of cholesterol and triglycerides synthesis.
Topics: Anticholesteremic Agents; Biological Products; Cholesterol; Diterpenes; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Hyperlipidemias; Molecular Structure; Pyrroles; Structure-Activity Relationship; Triglycerides; Tumor Cells, Cultured | 2021 |
Apolipoprotein E binds to and reduces serum levels of DNA-mimicking, pyrrolated proteins.
Topics: Adult; Amino Acid Sequence; Animals; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Biophysical Phenomena; DNA; Female; Humans; Hyperlipidemias; Kinetics; Lysine; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Mimicry; Protein Binding; Protein Interaction Domains and Motifs; Protein Processing, Post-Translational; Protein Structure, Tertiary; Proteins; Pyrroles | 2019 |
Promising role of ferulic acid, atorvastatin and their combination in ameliorating high fat diet-induced stress in mice.
Topics: Animals; Antioxidants; Atorvastatin; Coumaric Acids; Diet, High-Fat; Drug Therapy, Combination; Free Radical Scavengers; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Interleukin-6; Lipid Peroxidation; Liver; Male; Mice; NF-kappa B; Oxidative Stress; Pyrroles; Reactive Oxygen Species; Signal Transduction; Tumor Necrosis Factor-alpha; Weight Gain | 2013 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Characterization of statin dose response in electronic medical records.
Topics: Algorithms; Alleles; Atorvastatin; Cholesterol, LDL; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Electronic Health Records; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
Effect of extraction solvents and plant parts used on the antihyperlipidemic and antioxidant effects of Garcinia atroviridis: a comparative study.
Topics: Animals; Antioxidants; Atorvastatin; Flavonoids; Fruit; Garcinia; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Methanol; Phenols; Phytotherapy; Plant Extracts; Plant Leaves; Plant Stems; Pyrroles; Rats; Rats, Sprague-Dawley; Solvents; Water | 2014 |
Effect of vanillin on lipid profile in a model of hyperlipidemia, a preliminary study.
Topics: Animal Feed; Animals; Atorvastatin; Benzaldehydes; Cholesterol; Diet, High-Fat; Dietary Fats; Female; Free Radicals; Gene Expression Regulation; Heptanoic Acids; Hyperlipidemias; Lipids; Male; Oxygen; Pyrroles; Rats; Rats, Wistar; Triglycerides | 2013 |
Metabonomics study of the therapeutic mechanism of Gynostemma pentaphyllum and atorvastatin for hyperlipidemia in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Gynostemma; Heptanoic Acids; Hyperlipidemias; Lipid Metabolism; Liver; Magnetic Resonance Spectroscopy; Male; Metabolomics; Methylamines; Phosphatidylcholines; Phytotherapy; Plant Extracts; Pyrroles; Rats; Rats, Sprague-Dawley; Treatment Outcome; Triglycerides | 2013 |
Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
Topics: Animals; Apolipoproteins E; Atorvastatin; CD36 Antigens; Cholesterol; Cholesterol, Dietary; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Feedback, Physiological; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Inflammation Mediators; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pyrroles; RNA Interference; Scavenger Receptors, Class A; Stress, Physiological; Time Factors; Transfection | 2014 |
Myopathy after switching from brand to generic atorvastatin.
Topics: Aged; Atorvastatin; Blood Chemical Analysis; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Muscular Diseases; Polypharmacy; Pyrroles | 2013 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperuricemia; Kidney; Male; Middle Aged; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2014 |
A benign tumor as the apparent trigger for myopathy.
Topics: Aged; Atorvastatin; Female; Gynecologic Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leg; Leiomyoma; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Neoplasms; Pyrroles; Treatment Outcome; Uterine Neoplasms | 2014 |
Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Atorvastatin; C-Reactive Protein; Colchicine; Diet, High-Fat; Heptanoic Acids; Hyperlipidemias; Male; Nitrogen Oxides; Pyrroles; Rats; Rats, Sprague-Dawley | 2014 |
Cranberry juice, atorvastatin and back pain.
Topics: Anticholesteremic Agents; Atorvastatin; Back Pain; Beverages; Fruit; Heptanoic Acids; Herb-Drug Interactions; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Vaccinium macrocarpon | 2014 |
Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats.
Topics: Animals; Aorta; Atorvastatin; Biological Products; Combined Modality Therapy; Creatine Kinase; Diet, High-Fat; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Liver; Male; Muscular Diseases; Myocardium; Pyrroles; Rats; Ubiquinone | 2014 |
Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits.
Topics: Adipose Tissue; Animals; Arachidonate 5-Lipoxygenase; Atorvastatin; Heptanoic Acids; Hyperlipidemias; Inflammation; Lipid Metabolism; Male; Pyrroles; Rabbits | 2014 |
Hypolipidemic effect of fenugreek seeds and its comparison with atorvastatin on experimentally induced hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; India; Lipid Metabolism; Lipids; Male; Phytotherapy; Plant Extracts; Pyrroles; Rabbits; Triglycerides; Trigonella | 2014 |
Statin adverse effects: sorting out the evidence.
Topics: Atorvastatin; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Outcome Assessment, Health Care; Practice Guidelines as Topic; Pyrroles; Rhabdomyolysis; Risk Adjustment; Ubiquinone; Vitamins | 2014 |
Atorvastatin-mediated protection of the retina in a model of diabetes with hyperlipidemia.
Topics: Animals; Antioxidants; Atorvastatin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diet, Atherogenic; Heptanoic Acids; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Male; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrroles; Rats; Reactive Oxygen Species; Retina; Ubiquitin | 2014 |
Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cholesterol; Female; Humans; Hyperlipidemias; Hypothyroidism; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Triglycerides | 2015 |
Can atorvastatin calcium cause asymptomatic hypercalcemia?
Topics: Administration, Oral; Atorvastatin; Diagnosis, Differential; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercalcemia; Hyperlipidemias; Middle Aged; Pyrroles | 2014 |
Statin-associated myotoxicity in an incarcerated Indigenous youth - the perfect storm.
Topics: Adolescent; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Myositis; Native Hawaiian or Other Pacific Islander; Prisoners; Pyrroles; Vitamin D Deficiency | 2015 |
The hypolipidemic effect of artesunate and ursolic acid in rats.
Topics: Animals; Artemisinins; Artesunate; Atorvastatin; Cholesterol; Disease Models, Animal; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Rats; Triglycerides; Triterpenes; Ursolic Acid | 2015 |
Atorvastatin-induced dermatomyositis in a 47-year-old woman with Sjögren's syndrome.
Topics: Anticholesteremic Agents; Atorvastatin; Dermatomyositis; Female; Heptanoic Acids; Humans; Hyperlipidemias; Middle Aged; Pyrroles; Sjogren's Syndrome | 2015 |
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Topics: Arthritis, Rheumatoid; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Hyperlipidemias; Hypertension; Incidence; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2016 |
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor | 2008 |
Effects of atorvastatin on progression-regression of renal injury in hyperlipidemic chickens.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chickens; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heptanoic Acids; Hyperlipidemias; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Pyrroles | 2008 |
Molecule of the month.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Molecular Structure; Pyrroles; Structure-Activity Relationship | 2008 |
A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Lipids; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains | 2009 |
Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.
Topics: Apolipoprotein B-48; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intestinal Mucosa; Lipoproteins; Liver; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2009 |
Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Arteries; Constriction, Pathologic; Disease Progression; Female; Heptanoic Acids; Humans; Hyperlipidemias; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Secondary Prevention; Sex Distribution; Stroke; Treatment Outcome; Vertebrobasilar Insufficiency | 2009 |
Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Models, Economic; Myocardial Revascularization; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Atorvastatin; Blood Glucose; Body Weight; Brain; Dietary Fats; Female; Glutathione Peroxidase; Heptanoic Acids; Hyperglycemia; Hyperlipidemias; Insulin; Ketanserin; Lipid Peroxidation; Lipogenesis; Liver; Malondialdehyde; Mice; Mice, Inbred C57BL; Piperazines; PPAR gamma; Prazosin; Propranolol; Pyrroles; Superoxide Dismutase; Weight Gain | 2009 |
Antihyperlipidemic effect of the methanolic extract from Lagenaria siceraria Stand. fruit in hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol; Cucurbitaceae; Dietary Fats; Disease Models, Animal; Feces; Fruit; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Male; Phytotherapy; Plant Extracts; Pyrroles; Rats; Rats, Wistar; Triglycerides; Weight Gain | 2009 |
Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Dietary Fats; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Insulin; Lipids; Male; Pyrroles; Rabbits; Vasculitis | 2011 |
Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.
Topics: Animals; Atorvastatin; Chickens; Cholesterol; Disease Models, Animal; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Pyrroles; Severity of Illness Index; Triglycerides | 2010 |
Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use.
Topics: Allylamine; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pulse Therapy, Drug; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2009 |
Combined hyperlipidemia in patients with lysinuric protein intolerance.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cystatin C; Disease Progression; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2010 |
LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Topics: Adult; Aged; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Cohort Studies; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin | 2010 |
Effect of atorvastatin on activities of matrix metalloproteinases and chitotriosidase in male and female mice with experimental hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Enzyme Activation; Female; Heptanoic Acids; Hexosaminidases; Hyperlipidemias; Male; Matrix Metalloproteinases; Mice; Mice, Inbred ICR; Pyrroles; Triglycerides | 2009 |
Short-term effects of periodontal therapy as an adjunct to anti-lipemic treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chronic Periodontitis; Dental Plaque Index; Dental Scaling; Female; Follow-Up Studies; Gingival Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oral Hygiene; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Pyrroles; Root Planing; Treatment Outcome; Triglycerides | 2010 |
The utility of observational studies in clinical decision making: lessons learned from statin trials.
Topics: Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Decision Making; Epidemiologic Studies; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Observation; Pyrroles; Simvastatin | 2010 |
The influence of Sam-Chil-Geun (Panax notoginseng) on the serum lipid levels and inflammations of rats with hyperlipidemia induced by poloxamer-407.
Topics: Animals; Atorvastatin; Cholesterol; Cyclooxygenase 2; Drugs, Chinese Herbal; Heptanoic Acids; Hyperlipidemias; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-1; Lipids; Male; Poloxamer; Pyrroles; Rats; Rats, Wistar; Triglycerides; Tumor Necrosis Factor-alpha | 2010 |
Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Neuroprotective Agents; Pyrroles; Retrospective Studies; Severity of Illness Index; Simvastatin; Statistics as Topic; Stroke; Stroke Rehabilitation; Treatment Outcome | 2010 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Databases, Factual; Drug Therapy, Combination; Female; Health Records, Personal; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk; Risk Factors; Risk Reduction Behavior | 2010 |
Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Chronic Periodontitis; Cytokines; Female; Gingival Crevicular Fluid; Gingivitis; Heptanoic Acids; Humans; Hyperlipidemias; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Lipid Mobilization; Lipids; Male; Middle Aged; Periodontal Index; Pyrroles; Reproducibility of Results; Statistics, Nonparametric; Tumor Necrosis Factor-alpha | 2011 |
Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.
Topics: Adult; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Cholesterol 7-alpha-Hydroxylase; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Pyrroles | 2011 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2011 |
Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.
Topics: Animals; Atorvastatin; Combined Modality Therapy; Dietary Fats; Fatty Liver; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Organ Size; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1; Transaminases | 2011 |
Protective effect of dietary tocotrienols against infection and inflammation-induced hyperlipidemia: an in vivo and in silico study.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol; Cricetinae; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipid Metabolism; Lipoproteins, LDL; Male; Molecular Structure; Pyrroles; Tocotrienols | 2011 |
Not a graves' situation.
Topics: Atorvastatin; Biomarkers; Diagnosis, Differential; Drug Therapy, Combination; Eye Diseases; Fenofibrate; Graves Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oculomotor Muscles; Pyrroles; Thyroid Gland | 2011 |
Influence of atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity in mice with Triton WR 1339-induced lipaemia.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Liver; Male; Matrix Metalloproteinases; Mice; Mice, Inbred ICR; Polyethylene Glycols; Pyrroles; Scattering, Small Angle; Triglycerides; X-Ray Diffraction | 2011 |
Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin-A.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atorvastatin; Dietary Fats; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Hyperlipidemias; Inflammation; Interferon-gamma; Liver; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Piperazines; Pyrroles; Random Allocation; RNA, Messenger; Tumor Necrosis Factor-alpha | 2011 |
Inflammatory rebound phenomenon after abrupt withdrawal of statin is a mature point of view but not hypotheses.
Topics: Animals; Authorship; Heptanoic Acids; Humans; Hyperlipidemias; Male; Publishing; Pyrroles; Vasculitis | 2011 |
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2011 |
Protective effect of lemongrass oil against dexamethasone induced hyperlipidemia in rats: possible role of decreased lecithin cholesterol acetyl transferase activity.
Topics: Animals; Atorvastatin; Cholesterol; Cymbopogon; Dexamethasone; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Phytotherapy; Plant Extracts; Plant Oils; Pyrroles; Rats; Rats, Wistar; Terpenes; Triglycerides | 2011 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
Effect of ether- and water-soluble fractions of Carica papaya ethanol extract in experimentally induced hyperlipidemia in rats.
Topics: Animals; Atorvastatin; Carica; Cholesterol, HDL; Chromatography, Thin Layer; Dose-Response Relationship, Drug; Ethanol; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Mice; Olive Oil; Plant Extracts; Plant Oils; Pyrroles; Rats; Solvents; Spectrophotometry, Ultraviolet; Water | 2011 |
Proinflammatory cytokine levels in hyperlipidemic patients with periodontitis after periodontal treatment.
Topics: Adult; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Cytokines; Dental Scaling; Diet, Fat-Restricted; Female; Follow-Up Studies; Gingival Crevicular Fluid; Gingival Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Periodontitis; Pyrroles; Root Planing; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.
Topics: Adult; Animals; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; CD36 Antigens; CHO Cells; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cricetinae; Cricetulus; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL2; Liver; Macrophages; Male; Mice; Middle Aged; Paris; Particle Size; Postprandial Period; Pyrroles; Quinolines; Time Factors; Transfection; Treatment Outcome | 2012 |
Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
Topics: Animals; Atorvastatin; beta-Glucans; Biomarkers; Cholesterol, LDL; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Lipoproteins, LDL; Liver; Male; Matrix Metalloproteinases; Mice; Mice, Inbred ICR; Poloxamer; Pyrroles; Scattering, Small Angle; Time Factors; Triglycerides; X-Ray Diffraction | 2012 |
[Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm].
Topics: Anticholesteremic Agents; Atorvastatin; Bezafibrate; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pyrroles | 2012 |
[Statin-ezetimibe combination in hyperlipidemia treatment].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2012 |
Daming capsule restores endothelial dysfunction induced by high-fat diet.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Diet, High-Fat; Drugs, Chinese Herbal; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phytotherapy; Potassium Channels; Pyrroles; Rats; Rats, Wistar; Vascular Diseases; Vasoconstriction; Vasodilation | 2012 |
Periodontal status and hyperlipidemia: statin users versus non-users.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chronic Periodontitis; Cross-Sectional Studies; Dental Plaque Index; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontium; Pyrroles; Single-Blind Method; Triglycerides | 2013 |
Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia.
Topics: Azetidines; Fasting; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Postprandial Period; Pyrroles; Triglycerides | 2012 |
[Painless myocardial ischemia in patient with extensive constrictive atherosclerosis of coronary arteries].
Topics: Angioplasty; Anticholesteremic Agents; Asymptomatic Diseases; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Echocardiography; Electrophysiologic Techniques, Cardiac; Exercise Test; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
Effects of statins on oxidative stress and primed polymorphonuclear leukocytes in hyperlipidemic patients.
Topics: Adult; Apoptosis; Atorvastatin; Biomarkers; CD11b Antigen; Cells, Cultured; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Leukocyte Count; Male; Neutrophils; Oxidative Stress; Phorbol Esters; Pyrroles; Superoxides | 2012 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Topics: Adult; Aged; Analysis of Variance; Asian People; Atorvastatin; Biomarkers; Chi-Square Distribution; China; Cholesterol, HDL; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Gene Frequency; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pharmacogenetics; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2013 |
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2002 |
Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia.
Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type III; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2002 |
Aggressive lipid-lowering in stable patients with coronary artery disease.
Topics: Angioplasty; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Male; Multicenter Studies as Topic; Myocardial Ischemia; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic | 1999 |
Multiorgan failure induced by atorvastatin.
Topics: Aged; Atorvastatin; Chemical and Drug Induced Liver Injury, Chronic; Diagnosis, Differential; Fatal Outcome; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Multiple Organ Failure; Pyrroles | 2002 |
Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Glucose; Cholesterol; Collagen; Diabetes Mellitus, Experimental; Diet, Atherogenic; Fasting; Heptanoic Acids; Hyperlipidemias; Insulin; Lipoproteins, VLDL; Liver; Male; Pyrroles; Swine; Swine, Miniature; Triglycerides; Vitamin A; Vitamin E | 2002 |
The lower the LDL, the better.
Topics: Academies and Institutes; Atorvastatin; Heptanoic Acids; Human Experimentation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance Coverage; Insurance, Health; Lipoproteins, LDL; Pravastatin; Pyrroles | 2002 |
Atorvastatin and the dyslipidemia of early renal failure.
Topics: Adolescent; Adult; Aged; Atorvastatin; Body Mass Index; Cholesterol, LDL; Combined Modality Therapy; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Linear Models; Male; Middle Aged; Pyrroles; Renal Insufficiency; Risk Factors; Treatment Outcome | 2003 |
PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Disease; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pregnancy-Associated Plasma Protein-A; Pyrroles | 2003 |
Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy.
Topics: Adult; Aged; Apolipoproteins A; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Female; Fibronectins; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Probability; Prospective Studies; Pyrroles; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2002 |
Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51.
Topics: Atorvastatin; Bezafibrate; C-Reactive Protein; Drug Interactions; Estrogen Replacement Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Pyrroles | 2003 |
Indications and outcome of treatment of hyperlipidemia in pediatric allograft recipients.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Transplantation; Pyrroles | 2003 |
Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Calcium; Calcium Signaling; Coronary Artery Disease; Diabetes Complications; Diet; Disease Models, Animal; Endothelin-1; Endothelins; Heptanoic Acids; Hyperlipidemias; Male; Phosphorylation; Pyrroles; Receptor, Endothelin A; Receptors, Endothelin; Swine; Tyrosine | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies | 2003 |
[Comparative study of lipid lowering effect and influence on platelet aggregation of atorvastatin and simvastatin in patients ischemic heart disease with type II diabetes and combined hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Pyrroles; Simvastatin | 2003 |
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteries; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Diastole; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Stroke Volume; Systole; Treatment Outcome; Vascular Resistance | 2003 |
Lipid-lowering drugs and the risk of depression and suicidal behavior.
Topics: Adult; Aged; Atorvastatin; Case-Control Studies; Depression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Pyrroles; Regression Analysis; Risk Factors; Suicide | 2003 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
[Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Diabetes Complications; Ethics, Research; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Ireland; Pyrroles; Risk Factors; Scandinavian and Nordic Countries; United Kingdom | 2003 |
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E | 2003 |
Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
Topics: Aged; Atorvastatin; Cerebral Hemorrhage; Cerebrovascular Disorders; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Pyrroles; Time Factors | 2004 |
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Topics: Aged; Atorvastatin; Coronary Disease; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Uric Acid | 2004 |
A statin for a patient with hyperlipidemia and hepatitis C?
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholestyramine Resin; Diet; Exercise; Ezetimibe; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Risk Factors | 2004 |
Managing hyperlipidaemia: a real headache.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Headache Disorders; Heptanoic Acids; Humans; Hyperlipidemias; Male; Pyrroles | 2004 |
Amlodipine/atorvastatin (Caduet).
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles | 2004 |
Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Angiography; Coronary Disease; Endothelium, Vascular; Female; Hemostasis; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Male; Middle Aged; Peptide Fragments; Prospective Studies; Prothrombin; Pyrroles; Tissue Plasminogen Activator | 2004 |
Caduet treats two cardiovascular conditions at once.
Topics: Amlodipine; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Practice Guidelines as Topic; Pyrroles; Risk Assessment; Risk Factors | 2004 |
The lipid-regulating effects of atorvastatin on type 2 elder diabetes patients with hyperlipidemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Effect of withdrawal of statin on C-reactive protein.
Topics: Aged; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Risk Factors; Substance Withdrawal Syndrome | 2004 |
[Noninvasive assessment of the effect of atorvastatin on coronary microvasculature and endothelial function in patients with dyslipidemia].
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Circulation; Data Interpretation, Statistical; Echocardiography; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Microcirculation; Middle Aged; Models, Theoretical; Pyrroles; Time Factors; Triglycerides; Vasodilation | 2004 |
[Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus].
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Exertion-induced rhabdomyolysis in a patient on statin therapy.
Topics: Acute Kidney Injury; Atorvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Long-Term Care; Male; Middle Aged; Physical Exertion; Pyrroles; Rhabdomyolysis; Risk Assessment; Severity of Illness Index | 2005 |
Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
Topics: Atorvastatin; Cells, Cultured; Clofibric Acid; Cytokines; Fenofibrate; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Interleukin-1; Lipids; Monocytes; Plasminogen Activator Inhibitor 1; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Diet, Fat-Restricted; Drug Administration Schedule; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Pyrroles; Risk Factors; Smoking; Tissue Plasminogen Activator; Triglycerides | 2004 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
Topics: Adolescent; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hyperlipidemias; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Reversal of atherosclerosis with aggressive lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hyperlipidemias; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
Topics: Adult; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cholesterol; Cluster Analysis; Gene Expression Regulation; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Leukocytes; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pyrroles; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA; Time Factors | 2005 |
Effects of atorvastatin on inflammation and oxidative stress.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin Resistance; Isoprostanes; Middle Aged; Oxidative Stress; Pyrroles; Tunica Intima | 2005 |
Supratherapeutic response to ezetimibe administered with cyclosporine.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cyclosporine; Drug Interactions; Ezetimibe; Heart Transplantation; Heptanoic Acids; Humans; Hyperlipidemias; Immunosuppressive Agents; Male; Middle Aged; Postoperative Complications; Pyrroles | 2005 |
Effect of statin therapy on serum trace element status in dyslipidaemic subjects.
Topics: Adult; Antioxidants; Atorvastatin; Blood Chemical Analysis; Ceruloplasmin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Trace Elements | 2005 |
MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cellulose, Oxidized; Diet; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins; Male; Mice; Mice, Knockout; Pyrroles; Simvastatin; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2006 |
Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial.
Topics: Adolescent; Adult; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Prothrombin; Pyrroles; Thrombin; Thromboplastin; Treatment Outcome | 2006 |
Imaging of a regressive coronary soft plaque under lipid lowering therapy by multi-slice computed tomography.
Topics: Aspirin; Atorvastatin; Carotid Stenosis; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Radiography | 2006 |
Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biopsy, Needle; Disease Progression; Follow-Up Studies; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunoglobulin A; Immunoglobulin M; Immunosuppressive Agents; Kidney Glomerulus; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Organelles; Plasma Exchange; Pyrroles; Sclerosis; Severity of Illness Index; Software Design | 2006 |
Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Chickens; Cholesterol; Down-Regulation; Female; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Liver; Organ Size; Point Mutation; Pyrroles; Receptors, LDL; RNA, Messenger; Triglycerides | 2006 |
The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Stenosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles | 2006 |
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2006 |
Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism.
Topics: Antioxidants; Apoptosis; Atherosclerosis; Atorvastatin; Cell Membrane; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipid Peroxidation; Membrane Lipids; Models, Biological; Oxidative Stress; Pyrroles; X-Ray Diffraction | 2006 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Prescriptions; Drugs, Generic; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Metoprolol; Patient Compliance; Pharmacists; Pyrroles; Self Administration | 2006 |
[The effect of atorvastatin on the expression of CD55, CD59 in patients with hyperlipidemia].
Topics: Aged; Atorvastatin; Case-Control Studies; CD55 Antigens; CD59 Antigens; Complement Activation; Gene Expression Regulation; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2005 |
Influence of HMG-CoA-reductase inhibitors on the body fat status.
Topics: Adipose Tissue; Aged; Arterial Occlusive Diseases; Atorvastatin; Body Composition; Body Mass Index; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Simvastatin | 2006 |
Intracellular retention of hepatic serpins caused by severe hyperlipidemia.
Topics: Animals; Antithrombins; Atorvastatin; Chickens; Dietary Fats; Disease Models, Animal; Factor Xa Inhibitors; Fatty Liver; Heparin Cofactor II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intracellular Fluid; Lipid Metabolism; Lipids; Liver; Male; Pyrroles; Serpins | 2006 |
Autoimmune hepatitis triggered by statins.
Topics: Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
[Effects of atorvastatin on hyperlipidemia in kidney disease patients].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Diseases; Male; Middle Aged; Pyrroles; Renal Dialysis | 2007 |
[Blood lipid-regulation of stilbene glycoside from polygonum multiflorum].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Glucosides; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Male; Plant Tubers; Plants, Medicinal; Polygonum; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, LDL; RNA, Messenger; Stilbenes; Triglycerides | 2007 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.
Topics: Animals; Cholesterol; Drug Design; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Mice; Molecular Biology; Molecular Structure; Pyrroles; Structure-Activity Relationship | 2007 |
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Topics: Animals; Cricetinae; Dose-Response Relationship, Drug; Drug Design; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Models, Molecular; Molecular Structure; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Structure-Activity Relationship; Sulfonamides | 2007 |
NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Blood Pressure; Cell Line; Cholesterol; Cyclic GMP; Fibrinolytic Agents; Heptanoic Acids; Hyperlipidemias; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Myocytes, Smooth Muscle; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; PC12 Cells; Pulmonary Embolism; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2007 |
Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia.
Topics: Adipocytes; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Fatty Acid-Binding Proteins; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles | 2007 |
Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lactic Acid; Lipids; Male; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrroles; Rats; Rats, Sprague-Dawley | 2008 |
Glutathione S-transferase null and cholesteryl ester transfer protein TaqI B polymorphisms and lipid response to atorvastatin in Greek dyslipidaemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Female; Gene Silencing; Genetic Predisposition to Disease; Genotype; Glutathione Transferase; Greece; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Reference Values | 2008 |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2007 |
Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
Topics: Adult; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles | 2007 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
[What is new? Therapy with lipid lowering agents].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 1997 |
Atorvastatin: a new agent for hyperlipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles | 1997 |
[Prevention of cardiovascular diseases: Value of CSE inhibitors in the management of lipid metabolism disorders].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 1998 |
[Drug clinics. Drug of the month. Atorvastatin (Lipitor)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diet, Fat-Restricted; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Liver; Pyrroles; Receptors, LDL; Tablets; Triglycerides | 1998 |
[Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors | 1998 |
Atorvastatin in the management of an index patient with complete hepatic lipase deficiency.
Topics: Anticholesteremic Agents; Atorvastatin; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipase; Lipids; Liver; Male; Pyrroles | 1999 |
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Topics: Animals; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Male; Platelet Adhesiveness; Platelet Aggregation; Pyrroles; Rabbits; Simvastatin; Thrombosis | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Atorvastatin for protease inhibitor-related hyperlipidaemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Pyrroles; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
Atorvastatin and fibrinogen--a small subgroup shows extreme response.
Topics: Adult; Aged; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome | 1999 |
Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol; Dose-Response Relationship, Drug; Drug Interactions; Heptanoic Acids; Hyperlipidemias; Male; Nifedipine; Pyrroles; Rats; Rats, Sprague-Dawley | 1999 |
Atorvastatin and low-density lipoprotein subfractions profile in mixed hyperlipidaemia: a contributory effect of reduced hepatic lipase activity?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipase; Lipoproteins, LDL; Liver; Male; Middle Aged; Pyrroles | 1999 |
Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Topics: Apolipoproteins B; Atorvastatin; Biological Transport, Active; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Pyrroles | 2000 |
Coronary revascularization and aggressive lipid lowering.
Topics: Aspirin; Atorvastatin; Coronary Stenosis; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Metoprolol; Middle Aged; Myocardial Revascularization; Plasminogen Activators; Pyrroles; Risk Factors | 1999 |
Elevated lipoprotein(a) with statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Pyrroles | 2000 |
[Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Switzerland; Treatment Outcome | 2000 |
Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.
Topics: Atorvastatin; Calcium Carbonate; Cost-Benefit Analysis; Decision Support Techniques; Epoxy Compounds; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lipoproteins, LDL; Phosphates; Polyamines; Polyethylenes; Pyrroles; Sevelamer | 2000 |
Potential interaction between troglitazone and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Chromans; Diabetes Mellitus; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pyrroles; Retrospective Studies; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.
Topics: Acute Disease; Aged; Angioplasty, Balloon; Anti-Bacterial Agents; Arterial Occlusive Diseases; Atorvastatin; Drug Therapy, Combination; Fusidic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Pyrroles; Rhabdomyolysis; Risk Factors; Surgical Wound Infection; Tibial Arteries | 2000 |
Status report of lipid-lowering trials in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Risk Factors | 2000 |
Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Evidence-Based Medicine; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Myocardial Revascularization; Preventive Medicine; Pyrroles | 2000 |
The protective role of atorvastatin on function, structure and ultrastructure in the aorta of dyslipidemic rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Microscopy, Electron; Pyrroles; Rabbits | 2000 |
Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Drug Interactions; Endothelins; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Hyperlipidemias; Male; NG-Nitroarginine Methyl Ester; Pyrroles; Rabbits; Receptor, Endothelin A; Receptors, Endothelin; Receptors, Prostaglandin; Receptors, Thromboxane A2, Prostaglandin H2; Vasoconstriction | 2000 |
Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Diet; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Lauric Acids; Lipids; Lipoproteins, LDL; Liver; Male; Pyrroles; Quinolines; Triglycerides | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
Effect of atorvastatin on intracellular calcium uptake in coronary smooth muscle cells from diabetic pigs fed an atherogenic diet.
Topics: Animals; Atorvastatin; Caffeine; Calcium; Coronary Vessels; Cytoplasm; Diabetes Mellitus, Experimental; Diet, Atherogenic; Fluorescent Dyes; Fura-2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Vitro Techniques; Ionomycin; Ionophores; Male; Microscopy, Fluorescence; Muscle, Smooth, Vascular; Pyrroles; Sarcoplasmic Reticulum; Sodium; Swine; Swine, Miniature; Thapsigargin | 2001 |
Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
Topics: Animals; Atorvastatin; Bezafibrate; Cholesterol; Diphosphonates; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Hepatocytes; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Lipids; Macaca mulatta; Molecular Structure; Pyrroles; Rabbits; Receptors, LDL; Triglycerides | 2001 |
Statins have biphasic effects on angiogenesis.
Topics: Animals; Apolipoproteins E; Apoptosis; Atorvastatin; Carcinoma, Lewis Lung; Cell Differentiation; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphokines; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Neovascularization, Physiologic; Polyisoprenyl Phosphates; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
Topics: Adult; Aged; Antioxidants; Apolipoproteins; Arteriosclerosis; Atorvastatin; Autoantibodies; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunoassay; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles | 2002 |
The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Common; Female; Femoral Artery; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Tunica Intima | 2002 |
Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Microcirculation; Middle Aged; Nitric Oxide; Nitroprusside; Plethysmography; Prospective Studies; Pyrroles; Serotonin; Vasodilation | 2002 |
Routine statin treatment after acute coronary syndromes?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Patient Discharge; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2002 |
The catabolism of ornithine after intravenous loading in normal subjects and two patients with hyperprolinaemia type II.
Topics: Child; Child, Preschool; Female; Humans; Hyperlipidemias; Injections, Intravenous; Male; Ornithine; Pyrroles; Time Factors | 1970 |